CAJ | 학술논문

洛铂是具有自主知识产权的第三代铂类抗肿瘤药品.大量基础和临床研究表明,洛铂可有效抑制乳腺癌包括三阴性乳腺癌细胞的体外增殖；含洛铂方案治疗转移性乳腺癌(MBC)的疗效与国际标准的顺铂方案相当,安全性和耐受性更好,已成为MBC治疗的新选择,有待进一步开展优化临床合理用药的研究.
락박시구유자주지식산권적제삼대박류항종류약품.대량기출화림상연구표명,락박가유효억제유선암포괄삼음성유선암세포적체외증식；함락박방안치료전이성유선암(MBC)적료효여국제표준적순박방안상당,안전성화내수성경호,이성위MBC치료적신선택,유대진일보개전우화림상합리용약적연구.
As the third generation platinum antitumor drug with independent intellectual property rights,a number of basic and clinical research shows lobaplatin can effectively inhibit the proliferation of human breast cancer cell lines including triple-negative breast cancer in vivo.Compared with the cisplatinbased regimens,lobaplatin-based regimens have similar efficacy,and better safety profile.It becomes the new treatment option of metastatic breast cancer,and remains to be further study to optimize clinical rational drug use.